Media Center
Press Releases

Press Releases

17 Jul 17
Asia-Pacific colorectal cancer therapeutics market to approach $8 billion by 2023, says GBI Research

The colorectal cancer market across the Asia-Pacific (APAC) region, which covers China, India, Australia, South Korea and Japan, is set to rise from $4.7 billion in 2016 to almost $8 billion in 2023, representing a compound annual growth rate of 7.9%, according to business intelligence provider GBI Research.

Read post
12 Jul 17
Pharmaceutical companies are turning to deal making due to falling pipeline productivity, says GBI Research

Although the pharmaceuticals market continues to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy, according to business intelligence provider GBI Research.

Read post
03 Jul 17
Dermatology space to benefit most from five potential blockbusters by 2023, says GBI Research

Since 2014, five potential blockbuster drugs have been approved in the dermatology therapy area, within which they are forecast to achieve aggregate annual revenue of $12.4 billion by 2023, according business intelligence provider GBI Research.

Read post
27 Jun 17
Roche will remain oncology market leader to 2023, in an increasingly fragmented but growing therapy area

None of the products due to enter the oncology market by 2023 are expected to reach the same levels of success as the highest revenue-generating drugs currently in the market - such as Revlimid, Opdivo and Avastin - according to business intelligence provider GBI Research.

Read post
21 Jun 17
Mobile health (mHealth) increasingly popular as shift towards value-based medicine continues, says GBI Research

The uptake of mobile health (mHealth) which is used worldwide to deliver a range of healthcare services, including data collection and remote patient monitoring, will increase in the near future as the healthcare industry continues to shift towards value-based medicine, according to business intelligence provider GBI Research.

Read post